Preliminary efficacy data
PD, tumor, fibrosarcoma, SD
TUMOR, FIBROSARCOMA
Of the 24 participants who completed the treatment plan, 20 were evaluated for therapeutic efficacy. The tumor target lesions ranged from one to five. The lung, liver, and lymph nodes were the most common target lesion sites. Efficacy was evaluated based on the oncological evaluation analysis set and investigator assessment as per RECIST 1.1. No participants achieved CR or PR. The best overall response was assessed as SD, and the DCR was 40% (8/20; 95% CI 21.7–60.6). No DCR-dose correlation was observed. One participant with fibrosarcoma received 20 mg BID LXI-15029 and had SD at cycles 1 to 11 and then PD at cycle 12; the duration of SD was 344 days.Survival analysis showed that the overall median PFS of the participants from the date of the first dose of LXI-15029 was 29 days (95% CI: 29–141) (Fig. Progression-free survival of 20 evaluable participants